公开(公告)号：US20210268095A1

公开(公告)日：2021-09-02

申请号：US17180959

申请日：2021-02-22

Applicant: Pfizer Inc.

Inventor： Robert G.K. Donald ,  Rosalind Pan

IPC: A61K39/108 ,  A61K39/385 ,  A61P31/04 ,  A61P37/04

Abstract: This invention provides a polypeptide derived from E. coli or a fragment thereof, including compositions and methods thereof. In one embodiment, the compositions comprise a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides or conjugates thereof. In a further aspect, the compositions further comprise modified O-polysaccharide molecules derived from Klebsiella pneumoniae or conjugates thereof.

公开(公告)号：US20210145957A1

公开(公告)日：2021-05-20

申请号：US17161119

申请日：2021-01-28

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Amardeep Singh Bhupender Bhalla ,  Robert G.K. Donald ,  Jianxin Gu ,  Kathrin Ute Jansen ,  Rajesh Kumar Kainthan ,  Lakshmi Khandke ,  Jin-Hwan Kim ,  Paul Liberator ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Ingrid Lea Scully ,  Suddham Singh ,  Cindy Xudong Yang

IPC: A61K39/09 ,  C07K16/12 ,  C07K16/44 ,  A61K39/39 ,  A61K39/40 ,  A61K47/10 ,  A61K47/26

Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B. streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

公开(公告)号：US20200165582A1

公开(公告)日：2020-05-28

申请号：US16704744

申请日：2019-12-05

Applicant: Pfizer Inc.

Inventor： Jason Arnold Lotvin ,  Annaliesa Sybil Anderson ,  Robert G.K. Donald ,  Michael James Flint ,  Narender Kumar Kalyan ,  Kathrin Ute Jansen ,  Maninder K. Sidhu ,  Justin Keith Moran ,  Mark Edward Ruppen ,  Weiqiang Sun

IPC: C12N9/10 ,  C12N1/20 ,  C07K14/33

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.